Our Products
Infusion therapy
Appropriate dissolution of active pharmaceutical ingredient in fluids, sustains life
The field of infusion therapy implies the treatment of a patient with intravenously applied infusion solutions in order to enable a patient’s recovery or improvement of his illness. Depending on the underlying illness, the solution contains an appropriate active pharmaceutical ingredient.
This defines the type of definitive therapy: For example, fluid therapy aims to infuse larger volumes of water and appropriate electrolytes to patients for treatment of volume depletion such as major bleeding, dehydration or shock. Another example might be anti-infective therapy which means the treatment of a patient suffering from an infection with bacteria or fungi by infusing solutions containing antibiotics and antifungals.
The intelligent and new concept to optimize clinical processes
Vent free and modular intravenous set helps to define standards and increase the quality and safety of daily work in hospital.
Discharge Management
Hospitals, homecare providers, physicians and nurses are faced with the challenge of developing methods to assure that high quality treatment of patients can be provided in a home setting.
Risk prevention in infusion therapy
In modern medicine, infusion therapy is indispensable. It is therefore more important to learn more about risks associated with this therapy for both patients and healthcare workers.
PRODUCT CATALOGUE
S.No. | PRODUCT CODE | PRODUCT NAME | STRENGTH | INFUSION BAG PACK VOLUME |
|---|---|---|---|---|
1 | MPL2K1001 | CIPROFLOXACIN | 2MG/ML | 100 ML |
2 | MPL2K1002 | CIPROFLOXACIN | 2MG/ML | 200 ML |
3 | MPL2K1003 | LINEZOLID | 2MG/ML | 300ML |
4 | MPL2K1004 | MAGNESIUM SULFATE | 10MG/ML | 100ML |
5 | MPL2K1005 | MAGNESIUM SULFATE | 40MG/ML | 1000ML |
6 | MPL2K1006 | MAGNESIUM SULFATE | 40MG/ML | 1000ML |
7 | MPL2K1007 | MAGNESIUM SULFATE | 40MG/ML | 500ML |
8 | MPL2K1008 | MAGNESIUM SULFATE | 40MG/ML | 50ML |
9 | MPL2K1009 | MILRINONE LACTATE | 200MG/ML | 100ML |
10 | MPL2K1010 | MILRINONE LACTATE | 200MG/ML | 200ML |
11 | MPL2K1011 | PARACETAMOL | 10MG/ML | 100ML |
12 | MPL2K1012 | ROPIVACAINE | 2MG/ML | 100ML |
13 | MPL2K1013 | ROPIVACAINE | 5MG/ML | 200ML |
14 | MPL2K1014 | ROPIVACAINE | 2MG/ML | 100ML |
15 | MPL2K1015 | ROPIVACAINE | 5MG/ML | 200ML |
16 | MPL2K1016 | PROPOFOL | 10MG/ML | 50ML |
17 | MPL2K1017 | PROPOFOL (LCT with EDTA) | 10MG/ML | 100ML |
18 | MPL2K1018 | ZOLEDRONIC ACID | 4MG/100ML | 100ML |
Parenteral nutrition
Optimal nutrition status is vital throughout healing till wellness
The Nutrition Therapy is of central importance for our ability to handle diseases in general, infections, surgery and trauma in particular. The objective of the Nutrition Therapy is to maintain or improve the nutrition status by avoiding and treatment of malnutrition, maintaining body tissue and functioning plasma protein stores and to prevent macro- and micronutrient deficiency.
Nutritional support can be provided either orally (oral nutritional supplements) or through a feeding tube (Enteral Nutrition) or, when the digestive tract cannot be used, through an intravenous catheter that is inserted directly into the veins (Parenteral Nutrition).
The definitive type of nutrition therapy is largely depending on the patients’ condition, illness and needs. E.g. surgical patients in an ICU tend to have needs different from those patients undergoing anti-cancer treatment or chronic dialysis yet again need another nutritional support.
Processes in nutrition therapy
The field of Nutrition Therapy comprises all kinds of nutritional support from additions to normal oral diets for patients who do not or cannot eat sufficiently until complete parenteral nutrition regimes for patients who are unable to meet their nutritional needs by oral or enteral nutrition. Body reserves can normally make up for short fasting periods, however in already malnourished patients or patients at-risk of malnutrition even short periods without adequate nutrition present an additional hazard which could lead to a negative clinical outcome with increased morbidity and mortality.Depending on the populations, approximately 20-50% of hospitalized patients present with a state of malnutrition and thus need nutrition therapy. Generally speaking, two different approaches are available, the using the gastrointestinal system thus being referred to as enteral nutrition, the other bypassing the gastrointestinal system thus being referred to as parenteral nutrition.
The definitive type of nutrition therapy is largely depending on the patients condition, illness and needs. E.g. patients on the ICU tend to have needs different from those a burn patient might have, and patients undergoing anti-cancer treatment or chronic dialysis yet again need another nutritional support.
Plasma volume expanders
Hypovolemia from a range of etiologies can lead to severe morbidity and mortality unless blood volume and tissue perfusion are restored. The treatment of hypovolemia has included the improvement and restoration of blood volume loss by the intravenous infusion of plasma expanding therapeutic agents. These have included crystalloid and/or colloid solutions, and a brisk controversy as to which modality is better has engaged therapeutics for the past 30 years.
Dialysis and irrigation solutions
Dialysis serves the purpose of removing waste products from the body when the kidneys cannot do this anymore. There are various forms of dialysis with their own characteristics.
With haemodialysis the blood passes an artificial kidney via extracorporeal circulation. The artificial kidney removes waste products and fluid. This happens mainly by osmosis (diffusion) via a semipermeable membrane, and partly by convection that is via the transport of water and waste products forced by pressure (ultrafiltration).
With haemofiltration the transport of fluid and waste products under pressure (ultrafiltration) is the main process. The pores in these membranes are a little larger than those at haemodialysis and the filtered fluid has to be substituted. The advantage is that waste products with a larger molecular weight are also removed, thus better resembling the filtration process in the normal kidney. This may have a favourable effect on cardiovascular health. Haemodialysis almost always takes place in a dialysis centre, mostly three times a week during several hours or during night hours. It may in principle also be done at home, but hygiene and precision are very much required. Haemodialysis has the disadvantage that the patient usually is not allowed to drink much fluid and is restricted to a specific diet.
Irrigations are aqueous solutions. Active substances to be added have to be sufficiently water soluble
